Skip to main content

This website is intended for US healthcare professionals only.

INGREZZA® (valbenazine) capsules

FOR ADULTS WITH TARDIVE DYSKINESIA (TD)

REMISSION with INGREZZA

Rapid and robust efficacy at Week 6 with most seeing a response as early as Week 2*

Patient-reported improvements in TD impact at Week 24†

59% of patients reached symptomatic remission at Week 48‡

*80 mg significantly reduced AIMS by –3.2 (n=70) vs –0.1 (n=69) for placebo from baseline to Week 6 in KINECT 3. P≤0.001 vs placebo; adjusted for multiplicity. At Week 2, ~64% of patients (n/N=95/149) on INGREZZA 40 and 80 mg had a ≥1-point decrease from baseline in AIMS total score.

†Based on patient-reported improvements on the TD Impact Scale from baseline to Week 24 in open-label KINECT-PRO. No prespecified inferential statistical testing was conducted. Results are descriptive.

‡Post hoc analysis from open-label KINECT 4. 59% of patients (n/N=61/103) achieved remission at Week 48. Remission defined as ≤1 on each AIMS item 1-7 at Week 48. Results are descriptive.

Actor portrayal

FOR ADULTS WITH TARDIVE DYSKINESIA (TD)

HIGHLY EFFECTIVE1,*

More than reductions in TD severity—achieve remission with INGREZZA1,4,5,†

SEE REMISSION DATA

UNIQUELY SELECTIVE1,6,7,‡

Only INGREZZA: 100% on-target activity at VMAT27-9,‡

VIEW PHARMACOLOGY

THERAPEUTIC DOSE FROM DAY 11

Patients can start and stay on an effective dosage1

EXPLORE DOSING

PROVEN ACROSS THE WIDEST RANGE OF PATIENTS1,10

EXPLORE DOSING

FOR ADULTS WITH HUNTINGTON’S DISEASE (HD) CHOREA

control with INGREZZA

INGREZZA provided significant HD chorea control in a 12-week clinical study1,2*

*Significantly reduced TMC score by -4.6 (n=58) vs -1.4 (n=54) for placebo from baseline to end of treatment.

VIEW HD CHOREA EFFICACY
Number 1 most prescribed VMAT2 inhibitor. 8 years and counting

CONNECT WITH A REPRESENTATIVE

Contact a rep, request INGREZZA samples, sign up for email updates, and more.

CONTACT A REP
‡

Based on in vitro VMAT2 binding affinity of dihydrotetrabenazine (HTBZ) metabolites and the primary active metabolite of INGREZZA, + α HTBZ. The clinical significance of in vitro data is unknown and is not meant to imply clinical outcomes.

REFERENCES:

  1. INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.
  2. Data on file. Neurocrine Biosciences, Inc.
  3. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476-484.
  4. Correll CU, Citrome L, Singer C, et al. Sustained treatment response and global improvements with long-term valbenazine in patients with tardive dyskinesia. J Clin Psychopharmacol. 2024;44(4):353-361.
  5. Correll CU, Cutler AJ, Kane JM, McEvoy JP, Liang GS, O’Brien CF. Characterizing treatment effects of valbenazine for tardive dyskinesia: additional results from the KINECT 3 Study. J Clin Psychiatry. 2018;80(1):18m12278.
  6. Harriott ND, Williams JP, Smith EB, Bozigian HP, Grigoriadis DE. VMAT2 inhibitors and the path to INGREZZA (valbenazine). Prog Med Chem. 2018;57(1):87-111.
  7. Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361(3):454-461.
  8. Brar S, Vijan A, Scott FL, et al. Pharmacokinetic and pharmacologic characterization of the dihydrotetrabenazine isomers of deutetrabenazine and valbenazine. Clin Pharmacol Drug Dev. 2023;12(4):447-456.
  9. Skor H, Smith EB, Loewen G, O’Brien CF, Grigoriadis DE, Bozigian H. Differences in dihydrotetrabenazine isomer concentrations following administration of tetrabenazine and valbenazine. Drugs R D. 2017;17(3):449-459.
  10. Deutetrabenazine [package insert]. Parsippany, NJ: Teva Neuroscience, Inc.
  11. Stimming EF, Claassen DO, Kayson E, et al. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington’s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023;22(6):494-504.
  12. Data on file as of Q3 2024. Neurocrine Biosciences, Inc.
+Expand-Collapse

Important Safety Information

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA, can increase the risk of depression and suicidal thoughts and

Important Information

INDICATION & USAGE

INGREZZA® (valbenazine) capsules and INGREZZA® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington’s disease.